Spots Global Cancer Trial Database for A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Phase 1b Study Evaluating GS-9820 in Subjects With Lymphoid Malignancies
Official Title: A Phase 1b Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GS-9820 in Subjects With Lymphoid Malignancies
Study ID: NCT01705847
Conditions
Interventions
Study Description
Brief Summary: This study is to determine the appropriate dosing regimen of GS-9820 in subjects with lymphoid malignancies. This is a Phase 1b, open-label, dose-escalation and expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of GS-9820.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
VU Medical Center (VUmc), Amsterdam, , Netherlands
Academic Medical Center, Amsterdam, , Netherlands
St. Antonius Hospital, Nieuwegein, , Netherlands
Erasmus MC - Daniel den Hoed Cancer Center, Rotterdam, , Netherlands
Contact Details
Name: Henry Adewoye, MD
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
